Entero Therapeutics Amends S-1/A for Continuous Offering
Ticker: GRDX · Form: S-1/A · Filed: Jun 5, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | S-1/A |
| Filed Date | Jun 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1/A, Pharmaceuticals, Biotechnology, Capital Raise, SEC Filing, Emerging Growth Company, Smaller Reporting Company
Related Tickers: GRDX
TL;DR
**GRDX is gearing up for a capital raise, signaling potential dilution but also a lifeline for its drug pipeline.**
AI Summary
Entero Therapeutics, Inc. (GRDX) filed an S-1/A on June 5, 2025, as an amendment to its registration statement under the Securities Act of 1933, indicating a proposed sale of securities on a delayed or continuous basis pursuant to Rule 415. The company, formerly known as First Wave BioPharma, Inc. and AzurRx BioPharma, Inc., operates in the pharmaceutical preparations industry (SIC Code 2834). While specific revenue and net income figures are not detailed in the provided excerpt, the filing signals an intent to raise capital, which is crucial for a company in the drug development phase. The company's principal executive offices are located at 777 Yamato Road, Suite 502, Boca Raton, Florida, with Richard Paolone serving as Interim Chief Executive Officer. The S-1/A filing itself does not contain financial statements but rather updates the registration for a potential offering. The company is classified as a non-accelerated filer and a smaller reporting company, suggesting a market capitalization below the thresholds for larger filers. This amendment is a procedural step towards a future capital raise, essential for funding ongoing research and development in the pharmaceutical sector.
Why It Matters
This S-1/A filing is a critical procedural step for Entero Therapeutics, Inc. (GRDX) to potentially raise capital, which is vital for funding its pharmaceutical research and development pipeline. For investors, it signals an upcoming opportunity to participate in a public offering, but also highlights the company's need for external financing in a highly competitive biotech landscape. Employees and customers will be impacted by the success of these fundraising efforts, as sustained operations depend on adequate capital. The broader market will observe how GRDX navigates this capital raise, especially as a smaller reporting company in the competitive pharmaceutical preparations industry.
Risk Assessment
Risk Level: medium — The risk level is medium because the S-1/A filing itself doesn't provide financial details, but as a pharmaceutical company, GRDX faces inherent high risks related to drug development, clinical trials, and regulatory approvals. The classification as a 'smaller reporting company' and 'non-accelerated filer' suggests a smaller market capitalization and potentially fewer resources compared to larger competitors, increasing the risk associated with its capital-intensive operations.
Analyst Insight
Investors should monitor GRDX for the specifics of the upcoming offering, including pricing and dilution impact, before making any investment decisions. Evaluate the company's drug pipeline and clinical trial progress, as the success of these will be critical to the long-term value of any new shares issued.
Key Numbers
- 2025-06-05 — Filing Date (Date S-1/A was filed with the SEC)
- 333-287185 — SEC File Number (Unique identifier for the registration statement)
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
- 46-4993860 — IRS Employer Identification No. (Tax identification number for Entero Therapeutics, Inc.)
- 561-589-7020 — Business Phone (Contact number for Entero Therapeutics, Inc.)
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant filing S-1/A
- GRDX (company) — Ticker symbol for Entero Therapeutics, Inc.
- Richard Paolone (person) — Interim Chief Executive Officer of Entero Therapeutics, Inc.
- U.S. Securities and Exchange Commission (regulator) — Recipient of the S-1/A filing
- Sichenzia Ross Ference Carmel LLP (company) — Legal counsel for the registrant
- Lucosky Brookman LLP (company) — Legal counsel for the registrant
- First Wave BioPharma, Inc. (company) — Former name of Entero Therapeutics, Inc.
- AzurRx BioPharma, Inc. (company) — Former name of Entero Therapeutics, Inc.
- BioPharma d'Azur, Inc. (company) — Former name of Entero Therapeutics, Inc.
- Delaware (regulator) — State of incorporation for Entero Therapeutics, Inc.
FAQ
What is the purpose of Entero Therapeutics' S-1/A filing?
The S-1/A filing by Entero Therapeutics, Inc. on June 5, 2025, is an amendment to its registration statement under the Securities Act of 1933, indicating a proposed sale of securities on a delayed or continuous basis pursuant to Rule 415. This is a procedural step to enable future capital raising.
Who is the Interim CEO of Entero Therapeutics, Inc.?
Richard Paolone is the Interim Chief Executive Officer of Entero Therapeutics, Inc. His contact information is listed as 777 Yamato Road, Suite 502, Boca Raton, Florida, with a phone number of (561) 589-7020.
What industry does Entero Therapeutics, Inc. operate in?
Entero Therapeutics, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification (SIC) Code 2834. This places the company within the broader biotechnology and healthcare sectors.
What was Entero Therapeutics, Inc. formerly known as?
Entero Therapeutics, Inc. has undergone several name changes. It was formerly known as First Wave BioPharma, Inc. (name changed on 2021-09-21), AzurRx BioPharma, Inc. (name changed on 2014-11-03), and BioPharma d'Azur, Inc. (name changed on 2014-03-31).
What is Entero Therapeutics' classification regarding SEC filing status?
Entero Therapeutics, Inc. is classified as a non-accelerated filer and a smaller reporting company. This indicates that it does not meet the thresholds for larger market capitalization or public float that would qualify it as an accelerated or large accelerated filer.
Where are Entero Therapeutics' principal executive offices located?
The principal executive offices of Entero Therapeutics, Inc. are located at 777 Yamato Road, Suite 502, Boca Raton, Florida 33431. The business phone number is (561) 589-7020.
What are the potential implications for investors from this S-1/A filing?
For investors, this S-1/A filing signals that Entero Therapeutics, Inc. intends to raise capital through a securities offering. While it provides an opportunity to invest, it also implies potential dilution for existing shareholders. Investors should await details of the offering and assess the company's financial health and pipeline.
Which law firms are representing Entero Therapeutics in this filing?
Entero Therapeutics, Inc. is being represented by Sichenzia Ross Ference Carmel LLP, with Ross Carmel, Esq. and Avital Perlman, Esq., and Lucosky Brookman LLP, with Joseph M. Lucosky, Esq. and Steven Lipstein, Esq.
What is the fiscal year end for Entero Therapeutics, Inc.?
The fiscal year end for Entero Therapeutics, Inc. is December 31. This is a standard fiscal year end for many companies.
Why is the 'delayed or continuous basis' offering important for Entero Therapeutics?
An offering on a 'delayed or continuous basis' pursuant to Rule 415 allows Entero Therapeutics, Inc. to sell securities over time, providing flexibility to raise capital as needed and respond to market conditions. This is particularly beneficial for pharmaceutical companies that often require staggered funding for long-term R&D projects.
Industry Context
Entero Therapeutics operates within the pharmaceutical preparations industry (SIC Code 2834). This sector is characterized by high research and development costs, lengthy product development cycles, and significant regulatory hurdles. Companies in this space often rely on capital raises to fund clinical trials and bring new therapies to market. The competitive landscape includes both large, established pharmaceutical companies and numerous smaller biotechnology firms focused on niche therapeutic areas.
Regulatory Implications
As a pharmaceutical company, Entero Therapeutics is subject to stringent regulations from bodies like the FDA. The S-1/A filing itself is a regulatory requirement for offering securities. Potential investors should be aware of the inherent risks associated with drug development, including the possibility of clinical trial failures and the lengthy approval processes required by regulatory agencies.
What Investors Should Do
- Monitor future SEC filings for details on the proposed offering.
- Research the company's drug pipeline and clinical trial status.
- Evaluate the company's financial health and cash burn rate.
Key Dates
- 2025-06-05: Filing of S-1/A Amendment No. 1 — Indicates the company is preparing for a delayed or continuous offering of securities, signaling a need for capital to fund operations and development.
- 2021-09-21: Name change from First Wave BioPharma, Inc. — Represents a rebranding or strategic shift for the company.
- 2014-11-03: Name change from AzurRx BioPharma, Inc. — Further historical rebranding, indicating potential shifts in strategy or focus over time.
- 2014-03-31: Name change from BioPharma d'Azur, Inc. — The earliest recorded name change, highlighting a long history of corporate evolution.
Glossary
- S-1/A
- An amendment to a registration statement filed with the SEC on Form S-1, used for the initial registration of securities. (This filing indicates Entero Therapeutics is updating its registration for a potential future sale of securities.)
- Rule 415
- A rule that permits securities to be registered for delayed or continuous offerings. (The company is utilizing this rule, meaning the offering may not happen immediately and could be spread out over time.)
- Non-accelerated filer
- A filer that does not meet the thresholds for accelerated or large accelerated filer status, typically indicating a smaller market capitalization. (Classifies Entero Therapeutics as a smaller entity in terms of market presence and reporting requirements.)
- Smaller reporting company
- A company that meets certain criteria for revenue and public float, allowing for scaled-down disclosure requirements. (Suggests the company has a market capitalization below certain thresholds, impacting the level of detail required in SEC filings.)
- SIC Code 2834
- Standard Industrial Classification code for Pharmaceutical Preparations. (Defines the company's primary industry sector, which is drug manufacturing and development.)
Year-Over-Year Comparison
This filing is an amendment (S-1/A) to a registration statement, not a periodic report like a 10-K or 10-Q. Therefore, a direct comparison of financial metrics such as revenue growth, margin changes, or specific financial risks to a previous year's filing is not possible based on the provided excerpt. The filing primarily serves to update the registration for a potential future securities offering.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on June 5, 2025 by Richard Paolone regarding Entero Therapeutics, Inc. (GRDX).